Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SYDNEY, Australia, July 17, 2017 -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) would like to update shareholders on its current financial status subsequent to the closing of the recent U.S. capital raise and yesterday’s announcement of the expected 2nd milestone payment from Novartis.
Cash balance as at 30 June 2017 was AU$12.3 million. The additional proceeds received in July from the U.S. capital raise to accredited and institutional investors of approximately US$5.0 million (equivalent to approximately AU$6.5 million) together with the expected milestone payment from Novartis of US$1.0 million (equivalent to approximately AU$1.3 million) has extended the operational cash reach well into the last quarter of calendar year 2018, based on current management forecasts.
About Prima BioMed
Prima BioMed is listed on the Australian Stock Exchange, and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au
For further information please contact: U.S. Investors: Matthew Beck, The Trout Group LLC +1 (646) 378-2933; [email protected] Australian Investors/Media: Mr Matthew Gregorowski, Citadel-MAGNUS +61 (0) 422 534 755; [email protected]
